SCHEMBL27146597

SCHEMBL27146597

Cc1cc(Br)c(Cl)c(OCC(CCC(N)=O)NC(=O)O)c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 2/20 0.34
▸ KDM4E B2RXH2 4/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ TDP1 Q9NUW8 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ CYP2D6 P10635 2/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ MRGPRX4 Q96LA9 1/20 0.31
▸ MEN1 O00255 4/20 0.31
▸ KMT2A Q03164 4/20 0.31
▸ NPY1R P25929 1/20 0.31
▸ NPY2R P49146 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ MCL1 Q07820 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27008149 1.00 AAK1 (0.34) AAK1KDM4EALDH1A1TDP1CYP1A2
SCHEMBL23833250 0.87 AAK1 (0.50) AAK1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30193038 0.87 AAK1 (0.50) AAK1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23833248 0.87 AAK1 (0.50) AAK1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL27015309 0.83 PTGER1 (0.34) KDM4EALDH1A1TDP1L3MBTL1MEN1
SCHEMBL28967219 0.77 KDM4E (0.35) AAK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL23833065 0.76 AAK1 (0.47) AAK1
SCHEMBL22526458 0.76 AAK1 (0.47) AAK1
SCHEMBL30169241 0.76 AAK1 (0.47) AAK1
SCHEMBL30169243 0.75 AAK1 (0.48) AAK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 AAK1 2860/4885KDM4E 414/4885ALDH1A1 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback